PGIM Jennison Health Sciences Fund Q4 2025 Commentary

PGIM Investments42 FollowersFollow5ShareSavePlay(23min)CommentsSummaryU.S. equity markets capped a strong year of performance with modest gains in the fourth quarter.The PGIM Jennison Health Sciences Fund meaningfully outperformed its benchmark index during the fourth quarter of 2025.Healthcare's recovery in the second half of 2025 was driven by strong performance in high-growth subsectors, specifically biotechnology and pharmaceuticals.The sector continues to trade at an unprecedented discount of roughly 30% to the broader market, creating what we believe are compelling long-term value opportunities.We believe calendar year 2026 could offer some of the most attractive single-stock opportunities in many years, supported by improving sentiment and innovation.

Aldi Irvan Darmansyah/iStock via Getty Images Performance Recap U.S. equity markets capped a strong year of performance with modest gains in the fourth quarter. Resurging concerns about the durability of artificial intelligence (AI) development and the enormous levelsThis article was written byPGIM Investments42 FollowersFollowPGIM Investments, a subsidiary of PFI, is an investment adviser and the investment manager to all PGIM US open-end investment companies and manager or administrator to closed-end investment companies. Note: This account is not managed or monitored by PGIM Investments, and any messages sent via Seeking Alpha will not receive a response. For inquiries or communication, please use PGIM Investments' official channels.